Screener
Protagonist Therapeutics PTGX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeCurrent.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $3,459 | $5,339 |
| Accrued expenses and other payables | 21,667 | 28,269 |
| Deferred revenue | 9,659 | 9,550 |
| Operating lease liability | 2,396 | 2,283 |
| Total current liabilities | 37,181 | 45,441 |
| Operating lease liability - noncurrent | 6,820 | 8,040 |
| Total liabilities | 44,001 | 53,481 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's deferred revenue?
- Protagonist Therapeutics (PTGX) reported deferred revenue of $9.66M in Q2 2026.
- How has Protagonist Therapeutics's deferred revenue changed year-over-year?
- Protagonist Therapeutics's deferred revenue increased by 79.7% year-over-year, from $5.38M to $9.66M.
- What is the long-term trend for Protagonist Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's deferred revenue has grown at a -8.0% compound annual growth rate (CAGR), from $14.48M to $9.55M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Protagonist Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude